JP6513095B2 - ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 - Google Patents

ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 Download PDF

Info

Publication number
JP6513095B2
JP6513095B2 JP2016544133A JP2016544133A JP6513095B2 JP 6513095 B2 JP6513095 B2 JP 6513095B2 JP 2016544133 A JP2016544133 A JP 2016544133A JP 2016544133 A JP2016544133 A JP 2016544133A JP 6513095 B2 JP6513095 B2 JP 6513095B2
Authority
JP
Japan
Prior art keywords
substituted
dutpase
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016544133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502967A (ja
JP2017502967A5 (enExample
Inventor
ロバート ディー． ラードナー，
ロバート ディー． ラードナー，
ブルーノ ギトラン，
ブルーノ ギトラン，
Original Assignee
ユニバーシティ オブ サザン カリフォルニア
ユニバーシティ オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ サザン カリフォルニア, ユニバーシティ オブ サザン カリフォルニア filed Critical ユニバーシティ オブ サザン カリフォルニア
Publication of JP2017502967A publication Critical patent/JP2017502967A/ja
Publication of JP2017502967A5 publication Critical patent/JP2017502967A5/ja
Application granted granted Critical
Publication of JP6513095B2 publication Critical patent/JP6513095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016544133A 2014-01-03 2015-01-02 ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 Active JP6513095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923534P 2014-01-03 2014-01-03
US61/923,534 2014-01-03
PCT/US2015/010059 WO2015103489A1 (en) 2014-01-03 2015-01-02 Heteroatom containing deoxyuridine triphosphatase inhibitors

Publications (3)

Publication Number Publication Date
JP2017502967A JP2017502967A (ja) 2017-01-26
JP2017502967A5 JP2017502967A5 (enExample) 2018-02-08
JP6513095B2 true JP6513095B2 (ja) 2019-05-15

Family

ID=53494059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544133A Active JP6513095B2 (ja) 2014-01-03 2015-01-02 ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤

Country Status (7)

Country Link
US (2) US9790214B2 (enExample)
EP (1) EP3089964B1 (enExample)
JP (1) JP6513095B2 (enExample)
CN (1) CN106061952B (enExample)
CA (1) CA2935717C (enExample)
IL (1) IL246545B (enExample)
WO (1) WO2015103489A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941423B1 (en) 2013-01-07 2021-06-09 University of Southern California Deoxyuridine triphosphatase inhibitors
CN106061952B (zh) 2014-01-03 2022-01-28 南加州大学 含有杂原子的脱氧尿苷三磷酸酶抑制剂
DK3319939T3 (da) 2015-07-08 2025-02-24 Cv6 Therapeutics Ni Ltd Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787766A (fr) 1971-08-21 1973-02-19 Merck Patent Gmbh Imides d'acide glutarique et leur procede de preparation
US4304715A (en) 1979-06-08 1981-12-08 Derek Hudson Enkephalin analogues
JPS5839672A (ja) 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPH0674251B2 (ja) * 1986-02-07 1994-09-21 全薬工業株式▲会▼社 ビス−ジオキソピペラジン誘導体
JPS63101361A (ja) 1986-09-08 1988-05-06 ブリティッシュ・テクノロジー・グループ・リミテッド ジオキソピペリジン誘導体を含有する不安解消組成物
FR2644786B1 (fr) * 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US5962246A (en) 1996-03-29 1999-10-05 The University Of Medicine And Dentistry Of New Jersey dUTPase, its isoforms, and diagnostic and other uses
JPH09286786A (ja) 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
JP4524039B2 (ja) 1997-12-18 2010-08-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｓｒｃファミリーｓｈ２ドメインインヒビターとしてのピリドン
WO2000059874A1 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
WO2002083651A2 (en) 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
KR20070099031A (ko) 2005-01-25 2007-10-08 셀진 코포레이션 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물
WO2006135763A2 (en) 2005-06-09 2006-12-21 The Johns Hopkins University Inhibitors of dna repair enzymes and methods of use thereof
AP2514A (en) 2006-07-24 2012-11-23 Korea Res Inst Chem Tech HIV reverse transcriptase inhibitors
EP1939186A1 (en) 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
CA2726579C (en) 2008-06-03 2015-02-17 Taiho Pharmaceutical Co., Ltd. Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
US20110212467A1 (en) 2008-08-27 2011-09-01 University Of Southern California INHIBITORS OF dUTPase
JP2011231015A (ja) * 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
JP2013032293A (ja) 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩
MX2012006183A (es) 2009-11-30 2012-06-19 Taiho Pharmaceutical Co Ltd Potenciador del efecto antitumoral.
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
DK2508158T3 (da) 2011-04-04 2014-09-29 Arjo Hospital Equipment Ab Hejseværksapparat
EP2941423B1 (en) 2013-01-07 2021-06-09 University of Southern California Deoxyuridine triphosphatase inhibitors
CN106061952B (zh) 2014-01-03 2022-01-28 南加州大学 含有杂原子的脱氧尿苷三磷酸酶抑制剂
CN107613983B (zh) 2015-04-30 2021-05-04 大鹏药品工业株式会社 抗肿瘤剂的副作用减轻剂
KR20200039846A (ko) 2015-05-01 2020-04-16 다이호야쿠힌고교 가부시키가이샤 우라실 화합물의 신규 결정
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
DK3319939T3 (da) 2015-07-08 2025-02-24 Cv6 Therapeutics Ni Ltd Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors

Also Published As

Publication number Publication date
IL246545A0 (en) 2016-08-31
JP2017502967A (ja) 2017-01-26
EP3089964A4 (en) 2018-01-17
US10457673B2 (en) 2019-10-29
WO2015103489A1 (en) 2015-07-09
CA2935717A1 (en) 2015-07-09
CA2935717C (en) 2022-06-21
EP3089964B1 (en) 2021-02-24
US20180086746A1 (en) 2018-03-29
US9790214B2 (en) 2017-10-17
CN106061952B (zh) 2022-01-28
CN106061952A (zh) 2016-10-26
IL246545B (en) 2020-05-31
US20160326149A1 (en) 2016-11-10
EP3089964A1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
JP6513095B2 (ja) ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
JP6660993B2 (ja) デオキシウリジントリホスファターゼ阻害剤
US11479531B2 (en) Deoxyuridine triphosphatase inhibitors
US11198677B2 (en) Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US11124485B2 (en) Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US11168059B2 (en) Amino sulfonyl compounds
JP7445609B2 (ja) Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190409

R150 Certificate of patent or registration of utility model

Ref document number: 6513095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250